APP and Alzheimer disease: Pre-clinical models have identified a possible causative role of mitochondrial dysfunction toward AD pathology, as ROS production or antioxidant inhibition lead to elevated Aβ levels, possibly by altering amyloid precursor protein (APP) processing pathways (Lin and Beal, 2006).